Clinical Trial Update: Fulvestrant in Treating Patients With Recurrent, Persistent, or Metastatic Endometrial Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating fulvestrant for recurrent, persistent, or metastatic endometrial cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometrial Cancer

Drugs mentioned

• Fulvestrant (fulvestrant)

Snippet

Sponsor: Gynecologic Oncology Group | Conditions: Recurrent Uterine Corpus Carcinoma, Stage III Uterine Corpus Cancer AJCC v7 | Phase 2 | Status: UNKNOWN | Results posted: 2014-06-24